Navigation Links
Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser
Date:6/9/2011

MORRISTOWN, N.J., June 9, 2011 /PRNewswire/ -- Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director of NYU Vein Center and internationally recognized authority and pioneer in the field of vascular surgery, is once again leading the way with breakthrough techniques, being the first in the country to use the new VenaCure® 1470nm laser to treat varicose veins. The new laser uses a lower power output compared with other lasers resulting in effective vein closure.

The VenaCure 1470nm laser's light energy is accurately delivered through the NeverTouch® gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than with other wavelengths. The specially engineered fiber tip has a low power density that maximizes effectiveness and minimizes postoperative pain and bruising. The VenaCure 1470nm lasers are manufactured in AngioDynamics' Cambridge, U.K., facility, and have received the CE mark and 510k clearance.

Ongoing research studies have found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period.

"The 1470nm laser enables us to be more efficient during a procedure, we are able to treat veins much more efficiently, which ultimately improves the patients procedure experience," stated Dr. Kabnick. "That translates into quicker recovery for patients."

About Lowell S. Kabnick, MD, RPhS, FACS, FACPh

Lowell S. Kabnick, MD, RPhS, FACS, FACPh, a New York University Surgeon with offices in Manhattan and Morristown, NJ and Director of NYU Vein Center, is a world-renowned surgeon-teacher whose patient-centered approach to vein care has enabled the creation and improvement of many of today's most advanced noninvasive vascular surgery techniques. Recognized by his peers as an international leader in the diagnosis and treatment of venous disease, Dr. Kabnick was the first vascular surgeon in the United States to perform the VNUS Closure™ (radiofrequency) procedure and the VenaCure EVLT® (laser) procedure - two FDA-approved breakthrough technologies for treating the underlying causes of many varicose vein problems. For more information, please visit www.lowellkabnickmd.com.

Contact:
Lowell S. Kabnick, MD, RPhS, FACS, FACPh, lowell.kabnick@nyumc.org

New Jersey:
95 Madison Ave
Suite 415
Morristown, NJ 07960
Phone: 973-538-2000

New York:
NYU Vein Center
530 First Avenue
Suite 6D
New York, NY 10016
Phone: 212-263-8346


'/>"/>
SOURCE Lowell S. Kabnick
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... DIEGO , Dec. 6, 2016 /PRNewswire/ ... on the development of Conditionally Active Biologic ... and Beijing Sinobioway Group Company, Limited (Sinobioway) ... for development.  The specific program candidates and ... March 2015, BioAtla and Sinobioway entered into ...
(Date:12/6/2016)... , Dec. 6, 2016 In this age ... to be hopeful.  A special kind of sunglasses, from ... anxious life. Photo - http://photos.prnewswire.com/prnh/20161205/445444 ... Robert Buck, the psychotherapist who developed and patented the ... to overcoming anxiety and worry.  "Anxiety doesn,t have ...
(Date:12/5/2016)... Dec. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... pursuant to its previously-announced cash tender offers (the ... table below (collectively, the "Notes"), approximately $2.6 billion in ... and not validly withdrawn on or prior to ... time, today, December 5, 2016 (the "Early Tender ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 ... Winner in the Folio: Marketing Awards competition. Live From won in the Use ... pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most innovative ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those ... showing of hands. “The Road To Restoration” is the creation of published author, Thomas ... brass ring that you could reach out for, and grab, on the old carousels. ...
(Date:12/7/2016)... ... ... “Fred Rides a Train” allows readers to tag along on a special ... Train” is the creation of published author, Janet Morrison, who has been writing mostly ... "Fred, the Dog" series is her first attempt at writing for children. Janet, Fred, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... honored to present at the International Probiotic Association’s Washington DC workshop on November ... regulators to engage in dialog regarding probiotic dietary supplement regulations. , Dr. ...
Breaking Medicine News(10 mins):